Association of functional IL16 polymorphisms with cancer and cardiovascular disease: a meta-analysis
Metrics: PDF 284 views | Full Text 422 views | ?
Victor Hugo de Souza1, Josiane Bazzo de Alencar1, Bruna Tiaki Tiyo1, Hugo Vicentin Alves1, Evelyn Castillo Lima Vendramini1, Ana Maria Sell1,2 and Jeane Eliete Laguila Visentainer1,2
1 Post Graduation Program in Biosciences and Physiopathology, Department of Clinical Analysis and Biomedicine, State University of Maringá, Paraná, Brazil
2 Laboratory of Immunogenetics, Basic Health Sciences Department, State University of Maringá, Paraná, Brazil
|Victor Hugo de Souza,||email:||email@example.com|
Keywords: cytokines; alleles; polymorphism; single nucleotide; inflammation
Received: January 11, 2020 Accepted: August 05, 2020 Published: September 08, 2020
Introduction: Interleukin-16 (IL-16) is a chemotactic cytokine that is found to increase in Cancer and cardiovascular diseases (CVD). Single nucleotide polymorphisms (SNPs) in IL16 were associated with diseases. Thus, we conducted a systematic review and meta-analysis to evaluate possible associations between IL16 rs4778889, rs11556218, rs4072111, and rs1131445 SNPs and the risk for cancer or CVD.
Materials and Methods: This study was performed according to the PRISMA statement. Medline, Web of Science, and Scopus databases were systematically reviewed, and a meta-analysis was conducted.
Results: The analysis comprised 6386 individuals with cancer and 2415 with CVD. The SNP rs11556218 was significantly associated with an increased risk for cancer in Chinese in different genetic inheritance models. Also, to the best of our knowledge, this is the first meta-analysis to show an association of rs4778889 with an increased risk of gastric cancer and rs11556218 with an increased risk of CVD in Chinese.
Conclusions: Our meta-analysis suggested that the SNPs rs11556218 and rs4778889 of IL16 were associated with an increased risk for cancer in Chinese and rs11556218 with increased risk for CVD in Chinese, highlighting the need for further studies on the impact of these polymorphisms on cancer treatment and surveillance.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.